Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • AstraZeneca to invest $50 billion in U.S. R&D and manufacturing by 2030.

  • New Virginia-based facility to be company’s largest global manufacturing site.

  • Investment to generate tens of thousands of direct and indirect jobs across the U.S.

AstraZeneca (LSE:AZN) has unveiled plans to invest $50 billion in the United States by 2030, significantly expanding its manufacturing and research presence across the country. The announcement builds on America’s leadership in pharmaceutical innovation and aims to increase local production capabilities while accelerating the development of next-generation medicines.

A major component of this investment is the establishment of a new multi-billion dollar manufacturing facility in the Commonwealth of Virginia. Once operational, it will become AstraZeneca’s largest drug substance manufacturing site globally. The centre will focus on producing active ingredients for the company’s innovative weight management and metabolic treatments, including oral GLP-1, baxdrostat, oral PCSK9, and combination small molecule therapies. It will also produce a wide range of small molecules, peptides, and oligonucleotides using advanced technologies such as artificial intelligence, automation, and data analytics to enhance efficiency and scalability.

The Virginia facility follows a previously announced capital commitment of $3.5 billion made in November 2024. Combined, these initiatives are expected to create tens of thousands of highly skilled direct and indirect jobs throughout the country.

In addition to the new manufacturing plant, AstraZeneca's broader U.S. investment strategy includes a significant expansion of its research and development and production infrastructure. This includes:

  • Enhancement of the R&D campus in Gaithersburg, Maryland

  • A new cutting-edge research facility in Kendall Square, Cambridge, Massachusetts

  • Development of cell therapy manufacturing capabilities in Rockville, Maryland, and Tarzana, California

  • Expansion of continuous manufacturing operations in Mount Vernon, Indiana

  • Growth in specialty manufacturing in Coppell, Texas

  • Establishment of new facilities to support clinical trial supply

  • Continued advancement in R&D for novel therapeutics

Together, these initiatives are part of AstraZeneca’s strategic roadmap to achieve $80 billion in total revenue by 2030, with an anticipated 50% of that revenue to be generated from the U.S. market.

Howard Lutnick, U.S. Secretary of Commerce, commented on the announcement, emphasizing the importance of domestic pharmaceutical production. “For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the U.S. and will ensure medicine sold in our country is produced right here.”